HIGHLIGHTS
- What: The aim of this study was to analyze the behaviors of such as procalcitonin and_(CRP) during treatment with obinotuzumab (an anti-CD20 antibody). The authors showed that increases in procalcitonin and CRP values occur very quickly, in virtually every case, following the administration of obinutuzumab.
- Who: Krzysztof Gawronski and colleagues from the Department of Hematology, Military Institute of Medicine-National Research Institute, Szaserow Street , have published the article: Inflammatory Markers Significantly Increased in Patients Treated with Obinotuzumab for Lymphoproliferative Diseases, in the Journal: (JOURNAL) of 12/Dec/2022
SUMMARY
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.